Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1228 ARTÍCULOS , VIENDO DEL 1141 AL 1155

P300 Amplitude in Alzheimer's Disease: A Meta-Analysis and Meta-Regression

Hedges D, Janis R, Mickelson S, Keith C, Bennett D, Brown BL.

Clin EEG Neurosci. 2016 Jan;47(1):48-55. doi: 10.1177/1550059414550567. Epub 2014 Sep 23.

Subjective cognitive impairment: Towards early identification of Alzheimer disease

Garcia-Ptacek S, Eriksdotter M, Jelic V, Porta-Etessam J, Kåreholt I, Manzano Palomo S.

Neurologia. 2016 Oct;31(8):562-71. doi: 10.1016/j.nrl.2013.02.007. Epub 2013 Apr 17.

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease

Ji C, Xue GF, Li G, Li D, Hölscher C.

Rev Neurosci. 2016 Jan;27(1):61-70. doi: 10.1515/revneuro-2015-0021.

miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease

Mushtaq G, Greig NH, Anwar F, Zamzami MA, Choudhry H, Shaik MM, Tamargo IA, Kamal MA.

Med Chem. 2016;12(3):217-25. doi: 10.2174/1573406411666151030112140.

Inflammatory Process in Alzheimer's and Parkinson's Diseases: Central Role of Cytokines

Alam Q, Alam MZ, Mushtaq G, Damanhouri GA, Rasool M, Kamal MA, Haque A.

Curr Pharm Des. 2016;22(5):541-8. doi: 10.2174/1381612822666151125000300.

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia

Szeto JY, Lewis SJ.

Curr Neuropharmacol. 2016;14(4):326-38. doi: 10.2174/1570159x14666151208112754.

Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing

Roses AD, Akkari PA, Chiba-Falek O, Lutz MW, Gottschalk WK, Saunders AM, Saul B, Sundseth S, Burns D.

Expert Opin Drug Metab Toxicol. 2016;12(2):135-47. doi: 10.1517/17425255.2016.1133586. Epub 2016 Feb 2.

Insights into Mechanisms of Chronic Neurodegeneration

Diack AB, Alibhai JD, Barron R, Bradford B, Piccardo P, Manson JC.

Int J Mol Sci. 2016 Jan 12;17(1):82. doi: 10.3390/ijms17010082.

Comorbidities Matter: A Call to Improve Care for Hospitalized Patients with Alzheimer's and Parkinson's Disease

DiBartolo MC.

J Gerontol Nurs. 2016 Feb;42(2):4-5. doi: 10.3928/00989134-20160113-01.

Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins

Butterfield DA, Palmieri EM, Castegna A.

Expert Rev Proteomics. 2016;13(3):259-74. doi: 10.1586/14789450.2016.1149470.

Neuroprotective Effects of Fisetin in Alzheimer's and Parkinson's Diseases: From Chemistry to Medicine

Nabavi SF, Braidy N, Habtemariam S, Sureda A, Manayi A, Nabavi SM.

Curr Top Med Chem. 2016;16(17):1910-5. doi: 10.2174/1568026616666160204121725.

Phage M13 for the treatment of Alzheimer and Parkinson disease

Messing J.

Gene. 2016 Jun 1;583(2):85-89. doi: 10.1016/j.gene.2016.02.005. Epub 2016 Feb 8.

Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases

Irwin MH, Moos WH, Faller DV, Steliou K, Pinkert CA.

Drug Dev Res. 2016 May;77(3):109-23. doi: 10.1002/ddr.21294. Epub 2016 Feb 21.

Comparing Alzheimer's and Parkinson's diseases networks using graph communities structure

Calderone A, Formenti M, Aprea F, Papa M, Alberghina L, Colangelo AM, Bertolazzi P.

BMC Syst Biol. 2016 Mar 2;10:25. doi: 10.1186/s12918-016-0270-7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias